In vitro and in vivo analysis of B-Myb in basal-like breast cancer by Thorner, A. R. et al.
In Vitro and In Vivo Analysis of B-Myb in Basal-Like Breast 
Cancer
AR Thorner1,2,3, KA Hoadley2,3, JS Parker3, S Winkel3,4, RC Millikan3,4, and CM Perou2,3,5,#
1Curriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill, NC, 
27599 USA
2Department of Genetics, University of North Carolina, Chapel Hill, NC, 27599 USA
3Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 27599 
USA
4Department of Epidemiology, University of North Carolina, Chapel Hill, NC, 27599 USA
5Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, 
27599 USA
Abstract
A defining feature of basal-like breast cancer, a breast cancer subtype with poor clinical prognosis, 
is the high expression of “proliferation signature” genes. We identified B-Myb, a MYB family 
transcription factor that is often amplified and overexpressed in many tumor types, as being highly 
expressed in the proliferation signature. However, the roles of B-Myb in disease progression, and 
its mammary-specific transcriptional targets, are poorly understood. Here, we demonstrated that 
B-Myb expression is a significant predictor of survival and pathological complete response to 
neoadjuvant chemotherapy in breast cancer patients. We also identified a significant association 
between the G/G genotype of a nonsynonymous B-Myb germline variant (rs2070235, S427G) and 
an increased risk of basal-like breast cancer [OR 2.0, 95% CI (1.1-3.8)]. In immortalized, human 
mammary epithelial cell lines, but not basal-like tumor lines, cells ectopically expressing wild-
type B-Myb or the S427G variant showed increased sensitivity to two DNA topoisomerase IIα 
inhibitors, but not to other chemotherapeutics. In addition, microarray analyses identified many 
G2/M genes as being induced in B-Myb overexpressing cells. These results confirm that B-Myb is 
involved in cell cycle control, and that dysregulation of B-Myb may contribute to increased 
sensitivity to a specific class of chemotherapeutic agents. These data provide insight into the 
influence of B-Myb in human breast cancer, which is of potential clinical importance for 
determining disease risk and for guiding treatment.
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Breast cancer is not one disease, but rather, represents at least six subtypes (Perou et al., 
2000; Sorlie et al., 2003; Hu et al., 2006). These include luminal A, luminal B, normal-like, 
HER2-enriched, claudin-low and basal-like, each with unique gene expression profiles and 
distinct clinical outcomes. The majority of breast cancer cases (60-80 percent) comprise the 
luminal/estrogen receptor-α positive (ER+) tumors, while basal-like breast carcinoma 
accounts for 10-15 percent of all cases. The basal-like subtype, often clinically observed as 
“triple-negative” tumors (negative for ERα, PR, and HER2), is of particular interest because 
treatment options are limited to chemotherapy only and patients with this disease typically 
have poor outcomes. One contribution to the poor outcome of basal-like breast cancer 
patients may be their high cellular proliferation rates, which is manifested transcriptionally 
as the high expression of the “proliferation signature”; this is a dominant gene signature that 
is a marker of cell proliferation rates across multiple tumor types (Hu et al., 2006; Whitfield 
et al., 2006). B-Myb, a gene with known cell cycle control functions and implications in 
tumorigenesis (Sala, 2005), is one of approximately 100 genes that define the proliferation 
signature.
B-Myb is a member of the vertebrate MYB family of nuclear transcription factors. In 
humans this family is comprised of A-Myb (MYBL1), B-Myb (MYBL2), and c-Myb (MYB). 
Each family member is able to recognize and bind to the same DNA consensus sequence 
(PyAAC(G/T)G) to promote gene transcription; however, varying tissue-specific expression 
patterns, as well as protein-protein interactions with unique co-factors, suggests that distinct 
biological roles exist for each MYB family member (Rosinski & Atchley, 1998; Sala, 2005). 
Found in the genomes of both plants and animals, MYB proteins are conserved throughout 
evolution and control processes from flavonoid production to cellular proliferation (Rosinski 
& Atchley, 1998; Ito et al., 2001). In contrast to vertebrates, invertebrates contain only one 
MYB protein, which in Drosophila (dMYB) is phylogenetically and functionally 
complementary to vertebrate B-Myb, suggesting B-Myb to be the most ancient family 
member (Davidson et al., 2005). The expression of B-Myb, unlike c-Myb and A-Myb 
(Mucenski et al., 1991; Trauth et al., 1994; Toscani et al., 1997; Ness, 2003; Malaterre et 
al., 2007), is ubiquitously expressed in virtually all proliferating cells as a regulator of cell 
cycle progression and plays an essential role in vertebrate development; knocking out 
murine B-Myb causes early embryonic lethality (E4.5-6.5) resulting from unsuccessful inner 
cell mass formation (Tanaka et al., 1999).
MYB family members have been implicated in tumorigenesis for several decades. The c-
Myb proto-oncogene was first identified as the mammalian homolog of v-myb, which is the 
transforming gene transmitted by the avian myeloblastosis and E26 retroviruses causing 
acute leukemia in birds (Klempnauer et al., 1982; Leprince et al., 1983). A- and B-Myb were 
later discovered during low stringency screening of human cDNA libraries (Nomura et al., 
1988). The B-Myb chromosomal locus, 20q13, is amplified and/or highly expressed in a 
variety of tumor types including breast, prostate, liver and ovarian carcinomas, and in most 
cases this high expression portends a poor prognosis (Sala, 2005). B-Myb is also an 
important marker of poor outcome in embryonal tumors of the central nervous system 
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(CNS) (Pomeroy et al., 2002). Recently, a nonsynonymous B-Myb germline variant 
(rs2070235) causing a serine to glycine amino acid change (S427G) was linked to a decrease 
in overall cancer risk for neuroblastomas, chronic myelogenous leukemia, and colon cancers 
in a combined dataset of cases and controls (Schwab et al., 2007). However, the molecular 
roles of B-Myb in disease progression, as well as its transcriptional target genes in the 
mammary gland, are still poorly understood. To gain insight into B-Myb and its involvement 
in breast cancer, we analyzed the expression of B-Myb across the breast cancer subtypes, 
examined its relationship to survival and pathological complete response and the correlation 
of variant rs2070235 to disease risk. We also manipulated the expression of B-Myb and the 
S427G variant in normal and tumor derived mammary cell lines and observed alterations in 
drug sensitivity and cell cycle profiles.
RESULTS
High B-Myb Expression in Breast Tumors Predicts Poor Outcome
To asses the relevance of B-Myb gene expression across the breast cancer subtypes, breast 
tumor microarray data from the Netherlands Cancer Institute (NKI-295, n=295, (van de 
Vijver et al., 2002)) was analyzed. Tumor samples were classified into five breast cancer 
subtypes using a single sample centroid-based predictor as described (Hu et al., 2006). An 
ANOVA analysis performed on these stratified samples showed that B-Myb expression 
differs significantly across the subtypes and was highest in basal-like tumors (Figure 1).
To test for correlations between B-Myb mRNA expression alone and patient outcome, we 
analyzed the NKI patients not receiving adjuvant systemic treatment (i.e. local treatment 
only; n=165). This allowed us to better identify the prognostic abilities of B-Myb without the 
confounding data of treatment response. The NKI “local-only” tumors were rank ordered 
into halves (low/high) based on their B-Myb expression levels and analyzed for overall 
survival (OS) and relapse free survival (RFS) by Kaplan-Meier analysis. Poor OS and RFS 
were highly correlated (p<0.001) with B-Myb high expression levels in these NKI samples 
(Figure 2A, and RFS data not shown). B-Myb expression alone was also able to significantly 
predict OS on local-only treated luminal A subtype tumors (n=72) (Figure 2B), luminal B 
(n=26) (Figure 2C), HER2+/ER− (n=21) (Figure 2D), but not basal-like tumors (n=30) 
(Supplementary Figure 1A). We then evaluated the prognostic ability of B-Myb using two 
other published breast tumor microarray datasets (Miller et al., 2005; Wang et al., 2005). 
Wang et al., 2005 (n=286) consisted of microarrays on untreated, lymph-node-negative 
primary ER+ and ER-breast cancers with relapse data, and B-Myb was capable of predicting 
RFS in these patients (Figure 2E). On this same dataset, B-Myb also predicted RFS in the 
ER+ patient subset (n=209), but not the ER− subset (n=77) (Supplementary Figures 1B, C). 
Another dataset consisting of primary invasive tumors (Miller et al., 2005) (n=234) was 
tested and similar results were found (Figure 2F).
To determine if B-Myb expression was involved with pathologic complete response (pCR), 
we used the data of Hess et al., 2006, where microarrays were performed on pre-treatment 
breast tumors from patients receiving neoadjuvant paclitaxel, followed by 5FU-Adriamycin-
Cyclophosphamide (T/FAC; n=133). Again, samples were split into two groups based on B-
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Myb expression (low/high). B-Myb high expression was again associated subtype (data not 
shown) and with pCR, as calculated by chi-square test (p=0.008; Supplementary Table 1).
B-Myb Germline Variant (rs2070235) Increases Risk of Basal-Like Breast Cancer
A nonsysnonymous germline B-Myb variant exists that causes a serine to glycine 
substitution (rs2070235, S427G). This non-conservative change prompted us to look for 
correlations between this variant and baseline susceptibility risk in the population-based 
Carolina Breast Cancer Study/CBCS (Newman et al., 1995). Odds ratios for the B-Myb 
genotype and all breast cancer cases, luminal A, and basal-like cases, versus controls are 
presented in Table 1. There was no association between B-Myb genotype and all breast 
cancer (p=0.71); however a statistically significant association was observed for basal-like 
breast cancer (p=0.047), but not luminal A (p=0.14). No association was observed for B-
Myb genotype and the other breast cancer subtypes (luminal B, HER2+/ER− and 
unclassified: data not shown). Odds ratios were similar in African-Americans and 
Caucasians (likelihood-ratio tests/LRTs for interaction with race were not statistically 
significant). Among controls in the CBCS, allele frequencies for the B-Myb G allele were 
higher in African-Americans (0.27) than Caucasians (0.08).
Ectopic Expression of B-Myb Increases Sensitivity to TOP2A Inhibitors
Given B-Myb’s expression within the proliferation signature, evidence suggesting that 
rapidly growing tumors may be more chemotherapy sensitive, and the correlation between 
B-Myb expression and pathological complete response, we sought to determine if ectopic 
expression of B-Myb in vitro had an effect on sensitivity to chemotherapeutics. B-Myb, and 
the B-Myb S427G variant, were overexpressed in two hTERT-immortalized human 
mammary epithelial cell lines (HME-CC, ME16C) and two basal-like tumor derived lines 
(SUM102, SUM149) (Supplementary Figure 2). Low endogenous B-Myb levels were 
detectable by western blot in the tumor lines, and in all lines by microarray analysis for 
mRNA levels (Supplementary Figure 2 and data not shown). All cell lines were also 
genotyped for rs2070235 and identified as homozygous for the major allele. It is important 
to note that the two normal tissue derived cell lines have a basal-like phenotype when 
assessed by gene expression analysis (Troester et al., 2004), thus, these lines represent 
appropriate counterparts to the two basal-like tumor lines.
Cells ectopically expressing B-Myb, or S427G variant, were treated with a panel of 
chemotherapy agents including two DNA topoisomerase IIα (TOP2A) inhibitors 
(doxorubicin, etoposide), a DNA topoisomerase I inhibitor (camptothecin), a microtubule 
stabilizer (paclitaxel), a DNA alkylating agent (carboplatin), and an antimetabolite (5-
flurouracil), most of which are commonly used in breast cancer treatment. HME-CC cells 
overexpressing B-Myb, or variant, were approximately twice as sensitive to the two DNA 
topoisomerase IIα inhibitors, based on IC50 assays, compared to the parental cell lines, but 
showed no significant change in sensitivity to the other drugs (Figure 3A). To further test B-
Myb effects on chemotherapy sensitivity, another immortalized HMEC line (ME16C) and 
two basal-like tumor derived cell lines (SUM102, SUM149) were tested. The ME16C cell 
line was also sensitized to TOP2A inhibitors by B-Myb expression, but not to treatment with 
other chemotherapeutics (Figure 3B and data not shown); however, this sensitivity profile 
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was not observed in either of the two basal-like tumor derived lines (Figures 3C and D), 
where B-Myb expression had no apparent effect. The B-Myb S427G variant was also tested 
in each cell line for chemosensitivity and behaved similarly to the cells overexpressing wild-
type B-Myb (Figure 3A and data not shown).
Gene Expression Analysis of Cell Lines Ectopically Expressing B-Myb
To look for gene expression changes in cells overexpressing B-Myb, and to further assess the 
chemotherapy phenotype, microarrays were performed on the HME-CC cell lines. Under 
normal, non-confluent conditions, the only statistically significant expression difference 
(Significance Analysis of Microarrays/SAM analysis (Tusher et al., 2001) with a 3% false 
discovery rate/FDR) was B-Myb itself; also, no gene expression differences were observed 
between the B-Myb and B-Myb S427G-expressing cell lines. Since a chemotherapy-related 
phenotype was observed with TOP2A inhibitors, we tested the cell lines after treatment with 
the 72 hour IC50 dose of doxorubicin. In a two-class SAM analysis (i.e. doxorubicin-treated 
HME-CC control vs. doxorubicin-treated HME-CC+B-Myb), 217 genes were identified 
(FDR <3%; Supplementary Table 2).
An EASE (Expression Analysis Systematic Explorer) analysis (Hosack et al., 2003) was 
performed and many cell cycle related gene ontology categories were identified as being 
significantly enriched (Table 2). Therefore, in doxorubicin treated cells overexpressing B-
Myb there was significantly higher expression of many cell cycle genes compared to the 
treated control.
B-Myb is thought to be a transcriptional regulator of G2/M genes (Zhu et al., 2004). To 
determine if the 217-gene SAM list was enriched for genes within a particular phase of the 
cell cycle, each gene was assigned to a specific phase by comparing them to a known list 
derived from a precise cell cycle microarray time course experiment (Whitfield et al., 2002), 
or by literature search. Out of 217 significant genes, 101 genes were identified as being 
specifically induced during the cell cycle and 60/101 genes were assigned as G2/M-specific 
genes (Figure 4). In addition, previous known B-Myb target genes were present on the SAM 
list including CDC2, Cyclin B1, BIRC5, and the B-Myb binding partner, LIN-9.
Cell Cycle Profiles of B-Myb Overexpressing Cells
Since B-Myb expressing, doxorubicin treated cells produced a significant G2/M-enriched 
gene list, we hypothesized that the cell cycle profiles of these cells may be different than 
treated controls. B-Myb expressing HME-CC and empty vector controls were both treated 
with a range of doxorubicin doses for 48 hours and their cell cycle profiles analyzed for 
DNA content using flow cytometry. At zero dose or high dose of doxorubicin, the cell cycle 
profiles for both B-Myb overexpressing cells and controls were identical in terms of the 
percentage of cells in G1 and G2/M phase (Figure 5). However, at low and intermediate 
concentrations (10-35 nM) of doxorubicin there was a significant difference in the number 
of cells in G1 or G2/M with a larger percentage of B-Myb overexpressing cells in G1 versus 
controls, and a lower percentage of B-Myb overexpressing cells in G2/M (Figure 5A and 5B, 
respectively); very similar results were obtained with etoposide treatment (Supplementary 
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Figure 3). At high doses of doxorubicin or etoposide, regardless of B-Myb expression, the 
majority of cells arrested in G2/M.
DISCUSSION
Clinically defined as ER-, PR-, and HER2 not amplified, the basal-like subtype of breast 
cancer portends a poor prognosis. Basal-like breast cancer has an inherently high 
proliferation rate, which by microarray is identified by high expression of the “proliferation 
signature” genes; this signature has been identified in many publications, in many tumor 
types, and is highly enriched for cell cycle regulated genes (Whitfield et al., 2006). Here, we 
find that B-Myb, a gene highly expressed within the proliferation cluster, plays an important 
role in regulating cell cycle progression, which likely has effects on patient prognosis and 
response to chemotherapy.
We showed that B-Myb high expression was significantly associated with the poor outcome, 
basal-like breast cancer subtype and that B-Myb gene expression levels alone predicted poor 
outcomes in the absence of therapy (i.e. prognosis, Figure 2) and are correlated with 
achieving a pCR (i.e. prediction, Supplementary Table 1). Stratification of B-Myb 
expression, even within the luminal A, B, and HER2+/ER− subtypes, or ER+ tumors, was 
significantly associated with survival. Stratification of B-Myb expression within basal-like 
tumors did not predict outcomes, nor was outcome predicted in the ER− subset of the Wang 
et al., 2005 dataset (which includes basal-like tumors); however, these are inherently poor 
outcome tumors that significantly trend towards high B-Myb expression (Figure 1).
The B-Myb chromosomal locus, 20q13, is found amplified in a variety of cancers, including 
breast (Chin et al., 2006), and this amplification is linked to poor prognosis (Bergamaschi et 
al., 2006). Gene copy number analysis across breast tumor subtypes suggested that the 
genomic amplification of B-Myb was not enriched in the basal-like subtype, but instead was 
enriched in the luminal B subtype (Bergamaschi et al., 2006). Therefore, within luminal 
tumors, B-Myb amplification and expression is an event that appears to be selected for and 
portends a poor prognosis (Figures 2B, C). In basal-like tumors the high expression of B-
Myb may be due to other regulatory mechanisms, possibly by virtue of their inherently high 
proliferation rates, by amplification of transcription factor(s) targeting B-Myb, or by 
selectively enhanced promoter activity. This dual behavior of basal-like tumors, a subtype 
typical of chemo-responsiveness but with poor patient outcomes, has been described before 
and termed the “basal-like tumor paradox” (Carey et al., 2006), and the data presented here 
suggest that B-Myb may be a key regulator of this complex phenotype.
Recently, Schwab et al. 2007, linked the nonsynonymous B-Myb germline variant (S427G, 
rs2070235) to a decrease in overall cancer risk when combining neuroblastomas, chronic 
myelogenous leukemia, and colon cancers into a single dataset and comparing this grouping 
of cases to non-cancer bearing controls. While both studies are technically accurate (i.e. 
similar allele frequencies in the control populations; CBCS: homozygous major allele 
72.6%, heterozygous 24%, homozygous minor allele 3.4%; Schwab et al., 2007: 72.1%, 
27.3%, and 0.4%, respectively), the association of B-Myb rs2070235 genotype and basal-
like breast cancer susceptibility differs from the previous report and has not been described 
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before. Here, in a population based case-control study, we found that the rs2070235 minor 
allele was associated with increased risk of basal-like breast cancer but not other subtypes in 
the CBCS (Table 1). The discrepancy between the Schwab data and what is reported here 
may be due to differences between breast cancer and the cancers examined in the Schwab 
paper. Even amongst breast cancers there is significant heterogeneity across the subtypes in 
terms of the etiologic role of the B-Myb allele, and an analysis of breast cancer without 
subdivision would have missed the association of rs2070235 with the basal-like breast 
cancer subtype.
Presently, the function of the S427G variant is unknown. Our in vitro studies in breast 
epithelial cell lines showed neither a phenotypic difference between the overexpression of 
B-Myb or its variant on chemosensitivity relative to each other, nor did we observe a 
difference in their baseline gene expression patterns. It is temping to speculate that 
rs2070235 has functional consequences and somehow contributes to the etiology of basal-
like tumors. The B-Myb variant was found to be nearly ten-fold more frequent in African-
Americans (7%) versus non-African-Americans (0.8%) in the CBCS. This is relevant in 
light of recent data showing that premenopausal African-Americans are approximately twice 
as likely to develop basal-like tumors compared with premenopausal Caucasians (Carey et 
al., 2006; Millikan et al., 2008). Of note, Schwab et al., 2007 demonstrated that the B-Myb 
S427G protein was more stable than the wild-type protein. This increased stability may 
correspond to elevated B-Myb protein levels, possibly increasing transcriptional activity of 
G2/M cell cycle genes and leading to higher inherent proliferation rates. This alteration of 
cell cycle control may contribute to B-Myb’s influence on poor outcome breast cancers. 
Additional assays are required to more fully investigate the role of rs2070235 and other 
variants in B-Myb that may also lie in linkage disequilibrium with the G allele. This is an 
important area of investigation, since it is possible that one or more variants in B-Myb could 
contribute to the higher frequency of basal-like breast cancer among African-American 
breast cancer patients and may contribute to the pathophysiology of basal-like breast cancer.
Since chemotherapy is currently the only option for basal-like patients, we explored if 
increased B-Myb expression had any effect on chemosensitivity in vitro. We observed a 
statistically significant increase in sensitivity to two TOP2A inhibitors, doxorubicin and 
etoposide, in the HME-CC and ME16C cells overexpressing B-Myb or its variant, but this 
phenotype was not observed in the basal-like tumor derived cell lines (Figure 3). Also, there 
was no significant difference in chemosensitivity to the other tested drugs in any of the cell 
lines, which included camptothecin, a DNA topoisomerase I (TOP1) inhibitor. TOP2A, a 
nuclear enzyme that relaxes both negative and positive DNA supercoils by creating double-
stranded DNA breaks, is of particular importance for proper DNA duplication during S-
phase of the cell cycle (Smith et al., 1994). TOP2A inhibitors cause the enzyme to become 
trapped on double-strand DNA breakpoints, thereby causing G2 cell cycle checkpoint arrest. 
Since B-Myb is a G2/M regulating gene, increased B-Myb expression may be promoting the 
TOP2A-inhibitor treated cells through the G2 checkpoint via induction of downstream B-
Myb target genes. By facilitating cells through G2, with less regard for DNA damage, the B-
Myb overexpressing cells may attempt to cycle again, eventually leading to the increased 
sensitivity to TOP2A phenotype observed. TOP2A itself was on the B-Myb induced gene 
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list (Supplementary Table 2) and thus more of the target of doxorubicin and etoposide was 
present, adding to the observed sensitivity phenotype in B-Myb overexpressing cells.
In support of this hypothesis, the gene list identified by microarray analysis as being highly 
expressed in doxorubicin-treated, B-Myb overexpressing cells (Supplementary Table 2) was 
significantly enriched in genes required for G2/M progression. For example, this list 
included the newly described B-Myb interacting protein LIN-9, a protein required along 
with B-Myb for the transcription of G2/M genes (Osterloh et al., 2007). In addition, our B-
Myb target gene list contained many previously identified B-Myb targets including CDC2, 
Cyclin B1, and BIRC5 (Zhu et al., 2004; Osterloh et al., 2007). This gene list represents 
putative mammary B-Myb target genes and again suggests that B-Myb has its greatest effect 
on G2/M genes. In agreement with the gene list enrichment results, when B-Myb 
overexpressing cells were treated with low doses of doxorubicin or etoposide, more cells 
accumulated in G1 versus controls, suggesting that the control cell line was appropriately 
inhibiting cell cycle progression at G2, whereas B-Myb overexpressing lines were bypassing 
this checkpoint (Figure 5).
The results of this study enhance our understanding of the role of B-Myb in breast cancer by 
identifying new B-Myb target genes, by showing that this gene is highly expressed in basal-
like breast cancers, and by showing it is of prognostic value for survival and predictive value 
for pathological complete response. Also, we have described a significant correlation 
between a B-Myb variant and an increased risk of basal-like breast cancer. These findings 
point to B-Myb as a biomarker that is of potential clinical importance for determining 
disease risk and for guiding treatment. In addition to its role in basal-like cancers, B-Myb 
may also be of great importance in luminal tumors, a breast cancer subtype with relatively 
good prognosis, since B-Myb expression was capable of stratifying the poor from the good 
actors within this group, and it is within this group where B-Myb is occasionally amplified 
on the DNA level. The link between B-Myb high expression and increased chemotherapy 
sensitivity in vitro is mirrored by similar findings in vivo where we and others have shown 
that basal-like tumors are, on average, the most sensitive to multi-agent chemotherapy 
regimens that contain an anthracycline (Rouzier et al., 2005; Carey et al., 2007). It is 
unlikely that B-Myb expression alone is responsible for the chemotherapy sensitivity of 
basal-like tumors, but when coupled with the loss of TP53 function, which is known to 
occur in basal-like tumors (Sorlie et al., 2001), and the loss of RB function (Derenzini et al., 
2008; Herschkowitz et al., 2008), multiple important checkpoints are deficient in basal-like 
tumors and it is this lack of control that may ultimately prove to be their Achilles’ heel.
Materials and Methods
Cell Lines
hTERT-immortalized, human mammary epithelial cell lines (HME-CC, ME16C), and basal-
like breast cancer-derived lines (SUM102, SUM149) were cultured as described (Troester et 
al., 2004; Hoadley et al., 2007). Full-length, human B-Myb cDNA (GenBank NM_002466) 
was cloned into the pBabe.puro.GWrfA (Gateway Reading Frame A) vector using 
Gateway® Cloning Technology (Invitrogen, Carlsbad, CA, USA). Retrovirus was produced 
in Phoenix 293T cells by transfecting with ten micrograms of vector using Lipofectamine 
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2000 (Invitrogen), as per manufacturer’s instructions. Media was changed 24 hours post-
transfection and supernatants collected 12 hours later. Seventy-five micrograms of 
polybrene were added to the collected supernatants and applied to the mammary cell lines. 
Stable populations were selected by culturing in 1 ug/mL puromycin for HME-CC and 
ME16C, or 0.5 ug/mL puromycin for SUM102 and SUM149.
B-Myb variant (S427G) was created in the pBabe.puro.B-Myb expression vector using 
QuikChange® XL Site-Directed Mutagenesis Kit (Stratagene, Los Angeles, CA, USA).
Western Blot Analysis
Cells were grown in 10 cm tissue culture-treated dishes until 80 percent confluence, 
followed by harvest, protein isolation and quantification as previously described (Troester et 
al., 2004). Membranes were probed for B-Myb (sc-725; Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA), and β-actin (AC-15; Abcam, Cambridge, MA, USA), followed by 
anti-rabbit or anti-mouse IgG horseradish peroxidase-linked whole antibody (Amersham 
Biosciences) and detected using SuperSignal West Pico Chemiluminescent Substrate 
(Pierce, Rockford, IL, USA).
Cell Cycle Analysis
Cells were treated with a range of doxorubicin (0-70 nM) or etoposide (0-2 nM) doses and 
DNA content was analyzed using a modified propidium iodide staining assay. Briefly, one 
million cells were collected by trypsinization, washed in 1x PBS, and fixed in 70% ethanol 
at 4C overnight. Cells were washed with PBS/0.2% BSA and resuspended in 500 microliters 
of PBS/0.2% BSA and 100 micrograms RNaseA. Propidium iodide was added to a final 
volume of 50 micrograms, and cells incubated at 37C for 30 minutes. DNA content analysis 
was performed using a FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, 
USA). To determine fractions of cells in G1 and G2/M phases, histograms of DNA content 
were analyzed using Summit v4.3 software (Dako, Carpinteria, CA, USA) gating around 2N 
and 4N DNA content. Analyses were done on three separate days and mean values were 
calculated.
Cytotoxicity Assay
Cell line sensitivities to drugs were assessed using a modified mitochondrial dye conversion 
assay (Cell-Titer 96, Promega #G4100, Madison, WI, USA) as described (Troester et al., 
2004; Hoadley et al., 2007). Chemotherapeutics (carboplatin, doxorubicin, 5-fluorouracil, 
paclitaxel, etoposide, camptothecin) were purchased from Sigma (St. Louis, MO, USA). The 
72-hour inhibitory concentration that caused a 50% reduction in MTT dye conversion 
(IC50) was determined using nonlinear regression (SAS Statistical Software, Cary, NC, 
USA) (Vanewijk & Hoekstra, 1993). Differences in the IC50 estimates were tested by a 
traditional ANOVA test of nested models was performed using the R system for statistical 
computing (R Development Core Team, 2006 http://www.R-project.org).
Microarray Analysis
Five replicates each of HME-CC B-Myb-overexpressing and vector control cell lines were 
treated with the 72-hour IC50 dose of doxorubicin. Poly-A(+) RNA was collected (Micro-
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FastTrack2.0 mRNA Isolation Kit, Invitrogen) from treated control cells and B-Myb 
overexpressing lines, reverse transcribed and labeled using the Agilent Low RNA Input 
Linear Amplification Kit (Agilent Technologies, Santa Clara, CA, USA), and hybridized to 
Agilent Human 44K Custom Oligo microarrays as described (Hu et al., 2005). An untreated 
HME-CC cell line reference was co-hybridized to all arrays (e.g. untreated HME-CC vs. 
doxorubicin-treated empty vector HME-CC). Microarrays were scanned on an Axon 
Genepix 4000B microarray scanner and analyzed using GenePix Pro 5.1 software 
(Molecular Devices, Sunnyvale, CA, USA). Data was normalized using Lowess 
normalization on the Cy3 and Cy5 channels. Microarray data is available at the UNC 
Microarray Database [http://genome.unc.edu] and at the Gene Expression Omnibus 
(GSE11429).
Microarray Statistical Analyses
Supervised microarray analysis was performed by selecting genes with an absolute signal 
intensity of at least 30 units in both dye channels and data present in at least 70% of 
experimental samples. A two-class, unpaired Significance Analysis of Microarrays (SAM) 
was performed to identify significant genes associated with B-Myb expression with a false 
discovery rate (FDR) of less than 3% (Tusher et al., 2001).
The Netherlands Cancer Institute breast cancer dataset (NKI-295, n=295) was used for 
analysis of B-Myb expression across breast cancer subtypes (van de Vijver et al., 2002); 
however, only locally-treated tumors (no chemotherapy) were used in survival analyses 
(n=165). Association of B-myb expression states (rank ordered and split in halves: low/high) 
relative to survival was tested using the Cox-Mantel log-rank test and results visualized 
using Kaplan-Meier survival plots (WinSTAT v.2007.1). Testing the association of B-myb 
expression versus subtypes was performed using ANOVA. Three other published datasets 
were analyzed, as above, for survival (Miller et al., 2005; Wang et al., 2005) or pathological 
response (Hess et al., 2006) by chi-square using the R system for statistical computing.
B-Myb Genotyping (CBCS)
The Carolina Breast Cancer Study (CBCS) is a population-based, case-control study of 
breast cancer conducted in 24 counties of central and eastern North Carolina between 1993 
and 2001 (Newman et al., 1995; Millikan et al., 2003). B-Myb genotyping (rs2070235) was 
conducted using DNA extracted from peripheral blood lymphocytes for 1256 cases with 
subtype information (500 African-American, 756 Caucasian) and 1814 controls (679 
African-American, 1135 Caucasian). For complete details see Supplementary Materials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. B-Myb expression across breast cancer subtypes
The NKI breast tumor microarray dataset (n=295) was classified into the five intrinsic 
subtypes and box plots used to visualize B-Myb expression according to breast cancer 
subtypes. Statistical significance was calculated by ANOVA.
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Figure 2. High expression of B-Myb correlates with poor outcome
Kaplan-Meier survival analyses based on B-Myb expression values rank ordered into halves 
(low/high). (A-D) Overall survival (OS) of locally treated NKI tumor samples: (A) All 
subtypes combined (n=165), (B) Luminal A (n=72), (C) Luminal B (n=26), (D) HER2+/ER
− (n=21). (E) RFS, Wang et al., 2005 (n=286), a locally treated, lymph-node-negative tumor 
microarray dataset. (F) Miller et al., 2005 breast tumor microarray dataset (n=234).
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Figure 3. Drug sensitivities in B-Myb overexpressing cell lines
IC50 doses (72h) of chemotherapy on cell lines stably expressing vector control, B-Myb, or 
B-Myb S427G variant. Each MTT experiment was performed in triplicate and error bars 
represent 95% confidence intervals (*p<0.001 relative to vector control). (A) hTERT-
immortalized HMEC line HME-CC. (B) hTERT-immortalized HMEC line ME16C. (C) 
Basal-like tumor derived cell line SUM102 and (D) SUM149.
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Figure 4. Enrichment of G2/M phase genes in doxorubicin-treated B-Myb overexpressing HME-
CC cells
Significance Analysis of Microarray was used to identify 217 significant genes whose high 
expression was present in B-Myb overexpressing cells. These genes were then assigned to a 
specific phase of the cell cycle by comparing them to Whitfield et al., 2002, which identified 
101/217 genes as being specifically induced during the cell cycle. The graph shows to which 
phase of the cell cycle these 101 genes mapped.
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Figure 5. Cell cycle profile of HME-CC cells stably expressing B-Myb and treated with 
doxorubicin
Cell cultures were treated with a range of doses of doxorubicin for 48 hours followed by 
propidium iodide DNA content analysis. Percentage of cells in (A) G1 phase and (B) G2/M 
were calculated by gating based on DNA content. Error bars indicate standard deviations 
between three independent experiments.
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